SEI Investments
SPRY icon

SEI Investments’s ARS Pharmaceuticals SPRY Stock Holding History

SEI Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$838K Buy
104,643
+91,660
+706% +$788K ﹤0.01% 2398
2026
Q1 		$104K Sell
12,983
-61,824
-83% -$592K ﹤0.01% 3089
2025
Q4 		$872K Buy
74,807
+26,695
+55% +$260K ﹤0.01% 2244
2025
Q3 		$484K Sell
48,112
-36,970
-43% -$531K ﹤0.01% 2244
2025
Q2 		$1.48M Sell
85,082
-9,952
-10% -$144K ﹤0.01% 1763
2025
Q1 		$1.2M Sell
95,034
-13,239
-12% -$159K ﹤0.01% 1840
2024
Q4 		$1.14M Buy
+108,273
New +$1.52M ﹤0.01% 1885

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

SEI Investments's SPRY Position: Q2 2026 in Review

SEI Investments increased its ARS Pharmaceuticals (SPRY) stake by 706% in Q2 2026, buying an estimated $788K and bringing the position to 104,643 shares worth $838K. The position accounts for ﹤0.01% of the portfolio, ranked #2398.

SEI Investments first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.48M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • SEI Investments held 104,643 shares of ARS Pharmaceuticals worth $838K as of Q2 2026.
  • SEI Investments bought 91,660 ARS Pharmaceuticals shares in Q2 2026, an estimated $788K.
  • ARS Pharmaceuticals made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2398 holding.
  • SEI Investments first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SEI Investments's ARS Pharmaceuticals position peaked at $1.48M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.